CA2429426A1 — Isoxazole derivatives
Assigned to Takeda Pharmaceutical Co Ltd · Expires 2002-05-23 · 24y expired
What this patent protects
Compounds of the general formula (I) or their salts or prodrugs have excellent insulin secretion promoting and blood sugar decreasing effects and are lowly toxic, thus being useful as drugs, particularly preventive and therapeutic agents for diabetes and diabetic complication, wh…
USPTO Abstract
Compounds of the general formula (I) or their salts or prodrugs have excellent insulin secretion promoting and blood sugar decreasing effects and are lowly toxic, thus being useful as drugs, particularly preventive and therapeutic agents for diabetes and diabetic complication, wherein one of R1 and R2 is hydrogen or a substituent and the other is an optionally substituted cyclic group; W is a free valency or a divalent aliphatic hydrocarbon group; and Y is a group represented by the general formula: -OR3 (wherein R3 is hydrogen, optionally substituted hydrocarbyl, an optionally substituted heterocyclic group, or optionally substituted acyl) or carboxyl which may be converted into an ester or an amide.
Drugs covered by this patent
- Velsipity (Etrasimod Arginine) · Pfizer Inc.
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.